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Survival, clinical, immunological and hematological out-
comes of antiretroviral therapy among HIV-infected
children attending a public clinic in Kinshasa, Democratic
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Background: To assess the mortality, immunological,
hematological, and clinical outcomes of children initiating
antiretroviral therapy (ART) during the ﬁrst 5 years (Novem-
ber 2004 — October 2009) of a standardized HIV care and
treatment program at the Kalembe-Lembe pediatric hospital
in Kinshasa, DRC.
Methods: Retrospective analysis of routine clinical data
from a cohort of 603 HIV-infected children) 17 years of age
at ART initiation.
Results: Children initiated ART at a median age of 6.4
[interquartile range 3.2—10.5] years. At ART initiation,
27.1% were on treatment for tuberculosis, 54.6% were in
WHO stage III&IV, 52.8% had < 10 g/dL hemoglobin, 63.0%
had a CD4%) 15% (severe immunosuppression), 39.6% had
a weight-for-age Z score (WAZ)) -3 (severe underweight),
and 9.8% had previously received antiretrovirals. The ﬁrst
line regimens included stavudine or zidovudine, lamuvi-
dine, and nevirapine or efavirenz. During 1409.8 child-years
of follow-up (median follow-up, 28.7 months), 61 children
died: 38 during the ﬁrst 90 days of treatment (early mortal-
ity rate, 28.0/100 child-years; 95% Conﬁdence Interval (CI),
20.4—38.4) and 23 after 90 days (latemortality rate, 1.6/100
child-years; 95% CI, 1.9—2.5). The mean CD4% and WAZ rose
rapidly from 11.6% and -2.57 at baseline to 25.0% and -1.92
at 12 months before stabilizing above 28.0% and around -
1.80 between 18 and 48 months, respectively. The mean
height-for-age Z scores (HAZ) and hemoglobin increased
almost linearly from -2.23 and 9.8 g/dL at baseline to −1.78
and 10.8 g/dL at 12 months to -1.23 and 12.0 g/dL at 48
months, respectively. Children under two years of age at ART
initiation had greater and more sustained gains in weight,
height, CD4% and hemoglobin compared to children who
started ARTwhen at least two years of age (p < 0.01, p < 0.01,
p = 0.01, p < 0.01, respectively).
Conclusion: Despite late presentation in our clinic, good
clinical, immunological, and hematologic outcomes were
obtained within the ﬁrst 12 months and maintained through
48months of ART among children who survived the ﬁrst three
months. The high early mortality rate reﬂects obstacles to
health seeking behavior, early HIV diagnosis, and access to
timely ART initiation in Kinshasa.
doi:10.1016/j.ijid.2010.02.2037
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pparent virologic failures and blips in a suburban HIV
linic caused by laboratory errors in a commercial HIV-1
NA PCR assay
. Cariello ∗, T. Treadwell
MetroWest Medical Center, Framingham, MA, USA
Background: The use of commercial assays for quantiﬁca-
ion of viral RNA is a cornerstone in management of patients
ith HIV infection. We recently observed an increase in blips
nd apparent virologic failure not explained by poor adher-
nce or resistance and that resolved when our clinic changed
aboratories.
Methods: We retrospectively collected data on patients
ho were receiving highly active antiretroviral therapy
HAART) from October 2004 until June 2006 and who had
ne or more HIV-1 plasma viral load (VL) > 1,000 copies/mL.
e excluded patients who had interruptions in therapy
r had known poor adherence to clinic visits or medica-
ions.
Results: Our clinic changed our reference laboratory in
ecember 2005. In the previous 15 months, 38 patients on
AART had at least one VL > 1,000 copies/mL. Six patients
ad at least one VL > 10,000 copies/mL and 24 patients
ad more than 2 determinations > 1,000 copies/mL. In the
months following the lab change, 37/38 patients had
L < 400, 21/38 < 50, and only one patient had a VL >
00 copies/mL. One year later, 36/38 had no detectable
lasma viral RNA. All patients had stable CD4 lymphocyte
ounts (mean = 636 cells/mm3). Twenty-one patients had at
east one genotype during this period; no new mutations we
ound.
Conclusion: We believe that systematic errors in a com-
ercial laboratory contributed to apparent virologic failures
nd blips in this small group of patients.
oi:10.1016/j.ijid.2010.02.2038
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ntiretroviral resistance-associated mutations and
enomic diversity in reverse transcriptase and protease
ene among drug-naïve patients
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Background: Antiretroviral drugs (ARV) are being pro-
ided by Govt. of India since 2004 under 3 by 5 initiative
ed by WHO-UNAIDS. Despite wide spread use of ARV, little
nformation is available on the prevalence of transmitted
esistance-associated mutations in HIV-1, particularly from
orth India. The present study was designed for molec-
lar characterization of HIV-1 and identiﬁcation of ARV
esistance- associated mutations and naturally occurring
enotypic variation in reverse transcriptase (RT) and pro-
ease region of pol gene of HIV-1.
Methods: Seventy ARV drug-naïve HIV-1 sero-reactive
atients, newly registered in ART clinic of Lok Nayak Hos-
ital, were enrolled in the study after obtaining written
